CRISPR Therapeutics board member Brad Bolzon resigns after nearly a decade

CRISPR Therapeutics AG

Brad Bolzon, Chairman and Managing Director of Versant Ventures, resigned from CRISPR Therapeutics board effective March 28, 2023.
Resignation was not due to any dispute or disagreement with the company or its board.
Bolzon served nearly a decade and was instrumental in defining the company's vision and strategy since its founding.
No replacement named; company expressed gratitude for his contributions.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Bradley Bolzon

director

CRSP · CRISPR Therapeutics AG

Effective: 2023-03-28
Filed: March 29, 2023, 7:59 PM ET

On March 28, 2023, Bradley Bolzon, Ph.D. notified the Board of Directors of CRISPR Therapeutics AG (the “Company”) of his intention to resign as a director of the Company, effective as of the close of business on March 28, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bradley Bolzon resigned as director at CRISPR Therapeutics AG.

Action: resigned
Role: director

Exact text from the filing

On March 28, 2023, Bradley Bolzon, Ph.D. notified the Board of Directors of CRISPR Therapeutics AG (the “Company”) of his intention to resign as a director of the Company, effective as of the close of business on March 28, 2023.

View on SEC.gov

CRISPR Therapeutics AG filing history →

Source: SEC EDGAR

accession 0000950170-23-010439

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.